

January 13, 2023

Angela Drysdale  
VP, Regulatory Affairs  
Abbott Diagnostics Scarborough, Inc.  
10 Southgate Road  
Scarborough, ME 04074

Device: BinaxNOW COVID-19 Ag Card

EUA Number: EUA202537

Company: Abbott Diagnostics Scarborough, Inc.

Indication: Qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs samples collected by a healthcare provider from individuals who are suspected of COVID-19 within seven (7) days of symptom onset when tested at least twice over three days with at least 48 hours between tests or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested at least three times over five days with at least 48 hours between tests. Emergency use of this test is limited to authorized laboratories.

Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Dear Ms. Drysdale:

On August 26, 2020, based on your<sup>1</sup> request the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the BinaxNOW COVID-19 Ag Card, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3), for the indication stated in the letter.<sup>2</sup> Based on your request, FDA reissued the letter in its entirety

---

<sup>1</sup> For ease of reference, this letter will use the term “you” and related terms to refer to Abbott Diagnostics Scarborough, Inc.

<sup>2</sup> The August 26, 2020, letter authorized the BinaxNOW COVID-19 Ag Card for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in direct nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days symptom onset. Emergency use of this test was limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that

with revisions incorporated on December 16, 2020.<sup>3</sup> In addition, FDA established additional Conditions of Authorization in response to the continued emergence of new variants of SARS-CoV-2 on September 23, 2021.<sup>4</sup> Based on your requests, FDA granted updates to the authorized labeling on April 6, 2021,<sup>5</sup> January 7, 2022,<sup>6</sup> February 4, 2022,<sup>7</sup> and November 21, 2022.<sup>8</sup> Further, FDA revised the authorized uses and established one additional Condition of Authorization requiring updates to product labeling regarding repeat, or serial, testing, for all currently authorized SARS-CoV-2 antigen tests on November 1, 2022.<sup>9</sup>

On October 14, 2022, you requested to amend your EUA. Based on these request, and having concluded that revising the December 16, 2020, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the December 16, 2020, letter in its entirety with the revisions incorporated.<sup>10</sup> Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product<sup>11</sup> is now authorized for use

---

meet the requirements to perform moderate, high or waived complexity tests. This test was authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

<sup>3</sup> On December 16, 2020, the revisions to the August 26, 2020, letter and authorized labeling included: (1) revisions to the intended use and authorized labeling documents to clarify nasal swabs as anterior nasal (nares) swabs and add that “*Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed*” based on results of the updated clinical performance, (2) update the clinical performance section with the results of the recently completed clinical evaluation, as outline in Condition of Authorization U. in the August 26, 2020, letter, and (3) updates to the conditions of authorization to use language more consistent with recent authorizations.

<sup>4</sup> The Viral Mutation Revision Letter – September 23, 2021, can be accessed at:

<https://www.fda.gov/media/152406/download>.

<sup>5</sup> On April 6, 2021, your request was granted to update the shelf-life expiration date of the BinaxNOW COVID-19 Ag Card to 12 months at room temperature (28–30°C) based on the results of your ongoing stability studies. FDA also updated the Healthcare Provider and Patient Fact Sheets to reflect more recent authorizations.

<sup>6</sup> On January 7, 2022, your request was granted to update the shelf-life expiration date of the BinaxNOW COVID-19 Ag Card to 15 months at room temperature (28–30°C) based on the results of your ongoing stability studies.

<sup>7</sup> On February 4, 2022, your request was granted to; (1) add use of an additional nitrocellulose membrane option for manufacturing, and (2) minor updates to the BinaxNOW COVID-19 Ag CARD Instructions for Use and the BinaxNOW COVID-19 Ag CARD Procedure Card. FDA made some minor updates to the Fact Sheet for Healthcare Provider and Fact Sheet for Patients to reflect more recent authorizations.

<sup>8</sup> On November 21, 2022, your request was granted to update the BinaxNOW COVID-19 Ag Card to extend the shelf-life expiration date to 22 months when stored at 2 °C – 30°C, based on the results of your stability studies.

<sup>9</sup> The Repeat Testing Revision Letter - November 1, 2022, can be accessed at:

<https://www.fda.gov/media/162799/download>.

<sup>10</sup> The revisions to the December 16, 2020, letter include: (1) incorporating your response to Condition of Authorization (1) of the Repeat Testing Revision Letter dated November 1, 2022 to revise the authorized use(s) as required and described in Appendix A, and make various updates to the authorized labeling as required and described in Appendix B of the letter, (2) update the intended use to include use in “*individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested at least three times over five days with at least 48 hours between tests,*” (3) include results of additional reactivity studies, (4) updates to the Conditions of Authorization to incorporate Conditions related to circulating SARS-CoV-2 variants (Conditions Q. and R. below) from the Viral Mutation Revision Letter and addition of Condition of Authorization D. (below), and (5) updating the Letter of Authorization, the Fact Sheet for Healthcare Providers, and the Fact Sheet for Patients to reflect the revised intended use, and for consistency with language used in more recent authorizations.

<sup>11</sup> For ease of reference, this letter will use the term “your product” to refer to the BinaxNOW COVID-19 Ag Card used for the indication identified above.

consistent with the indication described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.<sup>12</sup>

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is included in the “BinaxNOW COVID-19 Ag CARD” Product Insert (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

### **I. Criteria for Issuance of Authorization**

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.<sup>13</sup>

### **II. Scope of Authorization**

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

---

<sup>12</sup> U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020).

<sup>13</sup> No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

## Authorized Product Details

Your product is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs samples collected by a healthcare provider from individuals who are suspected of COVID-19 within seven (7) days of symptom onset when tested at least twice over three days with at least 48 hours between tests or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested at least three times over five days with at least 48 hours between tests.

The SARS-CoV-2 nucleocapsid protein antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.

All negative results are presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and presence of clinical signs and symptoms consistent with COVID-19.

Testing of anterior nasal (nares) swab specimens using your product, as outlined in the “BinaxNOW COVID-19 Ag CARD” Product Insert, is limited to laboratories certified under CLIA that meet the requirements to perform high, moderate, or waived complexity tests. This test is authorized for use at the POC, i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

To use your product, an anterior nasal (nares) swab specimen is collected from the patient and the individual performing the test must follow instructions provided in the “BinaxNOW COVID-19 Ag CARD” Product Insert and the “BinaxNOW COVID-19 Ag CARD Procedure Card” when running the test procedure and interpreting the results. and tested by following the

The BinaxNOW COVID-19 Ag Card includes the materials or other authorized materials (as may be requested under Condition N. below), required to collection the anterior nasal sample and perform the test procedure, as described in the “BinaxNOW COVID-19 Ag CARD” Product Insert and the “BinaxNOW COVID-19 Ag CARD Procedure Card.”.

Your product requires use of the Positive Control Swab and Negative Control Swab or other authorized controls (refer to Condition N. below), that are run as outlined in the “BinaxNOW COVID-19 Ag CARD” Product Insert. Your product also requires the use of additional authorized materials and authorized ancillary reagents that are not included with your product and are described in the “BinaxNOW COVID-19 Ag CARD” Product Insert.

The labeling entitled “BinaxNOW COVID-19 Ag CARD” Product Insert and the “BinaxNOW COVID-19 Ag CARD Procedure Card” (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>), and the following fact sheets pertaining to the emergency use, is required

to be made available as set forth in the Conditions of Authorization (Section IV), and are collectively referred to as “authorized labeling”:

- Fact Sheet for Healthcare Providers: Abbott Diagnostics Scarborough, Inc.- BinaxNOW COVID-19 Ag Card
- Fact Sheet for Patients: Abbott Diagnostics Scarborough, Inc.- BinaxNOW COVID-19 Ag Card

The above described product, when accompanied by the authorized labeling as set forth in the Conditions of Authorization (Section IV) is authorized to be distributed to and used by authorized laboratories under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your authorized product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

### **III. Waiver of Certain Requirements**

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

#### **IV. Conditions of Authorization**

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

##### **Abbott Diagnostics Scarborough, Inc. (You) and Authorized Distributor(s)<sup>14</sup>**

- A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributor(s) must make your product available with the authorized labeling to authorized laboratories.
- C. You and authorized distributor(s) must make available on your website(s) the authorized labeling.
- D. You and authorized distributor(s) will include a physical copy of the “BinaxNOW COVID-19 Ag CARD” Product Insert and the “BinaxNOW COVID-19 Ag CARD Procedure Card” with each shipped kit of your product to authorized laboratories.
- E. You and authorized distributor(s) must inform authorized laboratories and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product and authorized labeling.
- F. Through a process of inventory control, you and authorized distributor(s) must maintain records of the authorized laboratories to which they distribute the test and number of tests they distribute.
- G. You and authorized distributor(s) must collect information on the performance of your product. You will report to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the product of which you become aware.
- H. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

---

<sup>14</sup> “Authorized Distributor(s)” are identified by you, Abbott Diagnostics Scarborough, Inc., in your EUA submission as an entity allowed to distribute your product.

**Abbott Diagnostics Scarborough, Inc. (You)**

- I. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).
- J. You must provide authorized distributor(s) with a copy of this EUA and communicate to authorized distributor(s) any subsequent revisions that might be made to this EUA and its authorized accompanying materials (e.g., Fact Sheets).
- K. You must comply with the following requirements pursuant to FDA regulations: Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).
- L. You must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that the tests released for distribution have the clinical and analytical performance claimed in the authorized labeling.
- M. If requested by FDA, you must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria, that you use to release lots of your product for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.
- N. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and shall not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to DMD/OHT7/OPEQ/CDRH and require appropriate authorization from FDA prior to implementation.
- O. You must evaluate the analytical limit of detection and assess traceability<sup>15</sup> of your product with any FDA-recommended reference material(s). After submission to and review and concurrence with the data by FDA, you must update labeling to reflect the additional testing. Such labeling updates must be made in consultation with, and require concurrence of, DMD/OHT7/OPEQ/CDRH.
- P. You must complete the agreed upon real-time stability study for your product and notify DMD/OHT7/OPEQ/CDRH of the testing results as they become available until completion of the study. After submission of the study data, and review of and concurrence with the data by FDA, you must update your product labeling to reflect the additional testing. Such labeling updates must be made in consultation with, and require concurrence of, DMD/OHT7/OPEQ/CDRH.

---

<sup>15</sup> Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material.

- Q. You must evaluate the impact of SARS-CoV-2 viral mutations on your product's performance. Such evaluations must occur on an ongoing basis and must include any additional data analysis that is requested by FDA in response to any performance concerns you or FDA identify during routine evaluation. Additionally, if requested by FDA, you must submit records of these evaluations for FDA review within 48 hours of the request. If your evaluation identifies viral mutations that affect the stated expected performance of your device, you must notify FDA immediately (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)).
- R. If requested by FDA, you must update your labeling within 7 calendar days to include any additional labeling risk mitigations identified by FDA, such as those related to the impact of viral mutations on test performance. Such updates will be made in consultation with, and require concurrence of, DMD/OHT7/OPEQ/CDRH.
- S. You must track adverse events, including any occurrence of false results and report to FDA pursuant to 21 CFR Part 803.

#### **Authorized Laboratories**

- T. Authorized laboratories using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating this labeling may be used, which may include mass media.
- U. Authorized laboratories using your product must use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including authorized clinical specimen types, authorized control materials, authorized ancillary reagents and authorized materials required to use your product are not permitted.
- V. Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- W. Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- X. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7/OPEQ/CDRH (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)) and you (via email: [ts.scr@abbott.com](mailto:ts.scr@abbott.com), or via phone by contacting Abbott Diagnostics Scarborough, Inc. Technical Service at 1-800-257-9525) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.
- Y. All operators using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.



**Abbott Diagnostics Scarborough, Inc. (You), Authorized Distributor(s) and Authorized Laboratories**

- Z. You, authorized distributors, and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

**Conditions Related to Printed Materials, Advertising and Promotion**

AA. All descriptive printed matter, advertising and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and meet the requirements set forth in section 502(a), (q)(1), and (r) of the Act, as applicable, and FDA implementing regulations.

BB. No descriptive printed matter, advertising or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

CC. All descriptive printed matter, advertising and promotional materials relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.
- This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

**V. Duration of Authorization**

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

---

Namandjé N. Bumpus, Ph.D.  
Chief Scientist  
Food and Drug Administration

Enclosure